Title:
CATION-INDEPENDENT MANNOSE-6-PHOSPHATE RECEPTOR BINDERS FOR TARGETED PROTEIN DEGRADATION
Document Type and Number:
WIPO Patent Application WO/2023/016828
Kind Code:
A3
Abstract:
The present invention relates to protein binding agents specifically binding the human cation-independent mannose-6-phosphate receptor (CI-M6PR), more specifically polypeptide agents comprising an immunoglobulin single variable domain (ISVD) specifically binding CI-M6PR at nano- to picomolar affinity, fused to further protein binding agents specifically binding extracellularly-accessible protein targets, such as membrane proteins, extracellular or secreted proteins. More specifically said CI-M6PR-specific ISVD recognizes CI-M6PR N-terminal domains 1, 2 and / or 3, thereby providing for means and methods for internalization, lysosomal targeting and degradation of agents comprising said ISVD, and of targets bound to said protein binding agents. The CI-M6PR binders disclosed herein are thus linked or fused to a further protein binding agent, in particular another antigen-binding protein, such as an ISVD or antibody, relevant for use in therapy, more specifically for treatment of diseases affected by said target antigen bound by said antigen-binding protein. More specifically disclosed herein are CI-M6PR ISVD fusions to antigen-binding proteins specifically binding EGFR, for treatment of cancer.
Inventors:
CALLEWAERT NICO (BE)
NAESSENS JUSTINE (BE)
VAN LANDUYT LINDE (BE)
NAESSENS JUSTINE (BE)
VAN LANDUYT LINDE (BE)
Application Number:
PCT/EP2022/071381
Publication Date:
March 30, 2023
Filing Date:
July 29, 2022
Export Citation:
Assignee:
VIB VZW (BE)
UNIV GENT (BE)
UNIV GENT (BE)
International Classes:
C07K16/28; A61P35/00
Domestic Patent References:
| WO2020185069A1 | 2020-09-17 | |||
| WO2020132100A1 | 2020-06-25 | |||
| WO2017100467A2 | 2017-06-15 |
Foreign References:
| US20180355017A1 | 2018-12-13 |
Attorney, Agent or Firm:
VIB VZW (BE)
Download PDF: